|
1
|
Negoita S, Feuer EJ, Mariotto A, Cronin
KA, Petkov VI, Hussey SK, Benard V, Henley SJ, Anderson RN, Fedewa
S, et al: Annual report to the nation on the status of cancer, part
II: Recent changes in prostate cancer trends and disease
characteristics. Cancer. 124:2801–2814. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cronin KA, Lake AJ, Scott S, Sherman RL,
Noone AM, Howlader N, Henley SJ, Anderson RN, Firth AU, Ma J, et
al: Annual report to the nation on the status of cancer, part I:
National cancer statistics. Cancer. 124:2785–2800. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lam VK and Papadimitrakopoulou V: Master
protocols in lung cancer: Experience from lung master protocol.
Curr Opin Oncol. 30:92–97. 2018.PubMed/NCBI
|
|
4
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI
|
|
5
|
Chen J, Sun Z, Zhang Y, Zeng X, Qing C,
Liu J, Li L and Zhang H: Synthesis of gibberellin derivatives with
anti-tumor bioactivities. Bioorg Med Chem Lett. 19:5496–5499. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Zhang H, Chen J, Zhao H, Zeng X,
Zhang H and Qing C: Antitumor and antiangiogenic effects of
GA-13315, a gibberellin derivative. Invest New Drugs. 30:8–16.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mo J, Kang M, Ye JX, Chen JB, Zhang HB and
Qing C: Gibberellin derivative GA-13315 sensitizes
multidrug-resistant cancer cells by antagonizing ABCB1 while
agonizes ABCC1. Cancer Chemother Pharmacol. 78:51–61. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen S and Tang J: Effects and mechanism
of GA-13315 on the proliferation and apoptosis of KB cells in oral
cancer. Oncol Lett. 14:1460–1463. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mayer RE, Hendrix P, Cron P, Matthies R,
Stone SR, Goris J, Merlevede W, Hofsteenge J and Hemmings BA:
Structure of the 55-kDa regulatory subunit of protein phosphatase
2A: Evidence for a neuronal-specific isoform. Biochemistry.
30:3589–3597. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Majchrzak-Celińska A, Słocińska M,
Barciszewska AM, Nowak S and Baer-Dubowska W: Wnt pathway
antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in
gliomas and SFRP1 methylation predicts shorter survival. J Appl
Genet. 57:189–197. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhan W, Han T, Zhang C, Xie C, Gan M, Deng
K, Fu M and Wang JB: TRIM59 promotes the proliferation and
migration of non-small cell lung cancer cells by upregulating cell
cycle related proteins. PLoS One. 10:e01425962015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dimitrakopoulos FD, Antonacopoulou AG,
Kottorou AE, Maroussi S, Panagopoulos N, Koukourikou I, Scopa C,
Kalofonou M, Koutras A, Makatsoris T, et al: NF-κB2 genetic
variations are significantly associated with non-small cell lung
cancer risk and overall survival. Sci Rep. 8:52592018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Siena L, Pace E, Ferraro M, Di Sano C,
Melis M, Profita M, Spatafora M and Gjomarkaj M: Gemcitabine
sensitizes lung cancer cells to Fas/FasL system-mediated killing.
Immunology. 141:242–255. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mou H, Moore J, Malonia SK, Li Y, Ozata
DM, Hough S, Song CQ, Smith JL, Fischer A, Weng Z, et al: Genetic
disruption of oncogenic Kras sensitizes lung cancer cells to fas
receptor-mediated apoptosis. Proc Natl Acad Sci USA. 114:3648–3653.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim D, Pertea G, Trapnell C, Pimentel H,
Kelley R and Salzberg SL: TopHat2: Accurate alignment of
transcriptomes in the presence of insertions, deletions and gene
fusions. Genome Biol. 14:R362013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seyednasrollah F, Laiho A and Elo LL:
Comparison of software packages for detecting differential
expression in RNA-seq studies. Brief Bioinform. 16:59–70. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Savinova OV, Hoffmann A and Ghosh G: The
Nfkb1 and Nfkb2 proteins p105 and p100 function as the core of
high-molecular-weight heterogeneous complexes. Mol Cell.
34:591–602. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rajsbaum R, García-Sastre A and Versteeg
GA: TRIMmunity: The roles of the TRIM E3-ubiquitin ligase family in
innate antiviral immunity. J Mol Biol. 426:1265–1284. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hao L, Du B and Xi X: TRIM59 is a novel
potential prognostic biomarker in patients with non-small cell lung
cancer: A research based on bioinformatics analysis. Oncol Lett.
14:2153–2164. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meroni G and Diez-Roux G: TRIM/RBCC, a
novel class of ‘single protein RING finger’ E3 ubiquitin ligases.
Bioessays. 27:1147–1157. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Esposito D, Koliopoulos MG and Rittinger
K: Structural determinants of TRIM protein function. Biochem Soc
Trans. 45:183–191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Uchil PD, Hinz A, Siegel S, Coenen-Stass
A, Pertel T, Luban J and Mothes W: TRIM protein-mediated regulation
of inflammatory and innate immune signaling and its association
with antiretroviral activity. J Virol. 87:257–272. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu F, Bardhan K, Yang D, Thangaraju M,
Ganapathy V, Waller JL, Liles GB, Lee JR and Liu K: NF-κB directly
regulates fas transcription to modulate fas-mediated apoptosis and
tumor suppression. J Biol Chem. 287:25530–25540. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pomerantz JL and Baltimore D: Two pathways
to NF-kappaB. Mol Cell. 10:693–695. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gilmore TD: Introduction to NF-kappaB:
Players, pathways, perspectives. Oncogene. 25:6680–6684. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cildir G, Low KC and Tergaonkar V:
Noncanonical NF-κB signaling in health and disease. Trends Mol Med.
22:414–429. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun SC: The noncanonical NF-κB pathway.
Immunol Rev. 246:125–140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Müller I, Beissert S and Kulms D:
Anti-apoptotic NF-κB and ‘gain of function’ mutp53 in concert act
pro-apoptotic in response to UVB+IL-1 via enhanced TNF production.
J Invest Dermatol. 135:851–860. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kaltschmidt B, Kaltschmidt C, Hofmann TG,
Hehner SP, Dröge W and Schmitz ML: The pro-or anti-apoptotic
function of NF-kappaB is determined by the nature of the apoptotic
stimulus. Eur J Biochem. 267:3828–3835. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
You BR, Han BR and Park WH:
Suberoylanilide hydroxamic acid increases anti-cancer effect of
tumor necrosis factor-α through up-regulation of TNF receptor 1 in
lung cancer cells. Oncotarget. 8:17726–17737. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brojatsch J, Naughton J, Rolls MM, Zingler
K and Young JA: CAR1, a TNFR-related protein, is a cellular
receptor for cytopathic avian leukosis-sarcoma viruses and mediates
apoptosis. Cell. 87:845–855. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou X, Hao Q, Liao P, Luo S, Zhang M, Hu
G, Liu H, Zhang Y, Cao B, Baddoo M, et al: Nerve growth factor
receptor negates the tumor suppressor p53 as a feedback regulator.
Elife. 5(pii): e150992016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Choi KE, Hwang CJ, Gu SM, Park MH, Kim JH,
Park JH, Ahn YJ, Kim JY, Song MJ, Song HS, et al: Cancer cell
growth inhibitory effect of bee venom via increase of death
receptor 3 expression and inactivation of NF-kappa B in NSCLC
cells. Toxins (Basel). 6:2210–2228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen M, Wang X, Zha D, Cai F, Zhang W, He
Y, Huang Q, Zhuang H and Hua ZC: Apigenin potentiates TRAIL therapy
of non-small cell lung cancer via upregulating DR4/DR5 expression
in a p53-dependent manner. Sci Rep. 6:354682016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yaguchi H, Okumura F, Takahashi H, Kano T,
Kameda H, Uchigashima M, Tanaka S, Watanabe M, Sasaki H and
Hatakeyama S: TRIM67 protein negatively regulates ras activity
through degradation of 80K-H and induces neuritogenesis. J Biol
Chem. 287:12050–12059. 2012. View Article : Google Scholar : PubMed/NCBI
|
